Is 3.75 mg Mirtazapine Safe to Take?
A 3.75 mg dose of mirtazapine is below the FDA-approved starting dose and is not supported by official prescribing guidelines, though emerging evidence suggests it may be safe for specific off-label uses like insomnia.
FDA-Approved Dosing and Safety Profile
The FDA-approved starting dose for mirtazapine is 15 mg once daily, preferably in the evening, with dose adjustments up to 45 mg/day for major depressive disorder 1. Taking 3.75 mg represents only 25% of the recommended starting dose and falls outside standard prescribing parameters.
However, the FDA label does not explicitly contraindicate lower doses—it simply doesn't provide guidance on sub-therapeutic dosing. The primary safety concerns with mirtazapine at therapeutic doses include 1:
- Suicidality risk (particularly in younger patients)
- Low white blood cell count (agranulocytosis)
- Serotonin syndrome (especially with other serotonergic drugs)
- Somnolence and sedation
- QT prolongation
- Angle-closure glaucoma
Ultra-Low Dose Evidence
The most recent evidence from 2026 demonstrates that 3.75 mg mirtazapine improved insomnia symptoms in 47% of veterans without significant next-day effects 2. This retrospective study showed meaningful decreases in Insomnia Severity Index scores, suggesting safety and tolerability at this ultra-low dose for insomnia specifically.
A 2013 study found that 7.5 mg mirtazapine did not impair driving performance compared to 15 mg, though both doses produced subjective somnolence 3. This suggests lower doses may reduce functional impairment while maintaining some therapeutic effects.
Key Safety Considerations at 3.75 mg
At this ultra-low dose, you would expect:
- Reduced risk of serious adverse events compared to therapeutic doses, as most dose-dependent toxicities (agranulocytosis, serotonin syndrome, cardiovascular effects) are less likely at sub-therapeutic levels
- Primarily sedative/antihistaminic effects rather than antidepressant activity, as mirtazapine's antihistamine (H1) effects predominate at lower doses
- Minimal drug interactions compared to standard doses, though caution remains with CYP3A4 inhibitors/inducers and serotonergic agents 1
Clinical Caveats and Contraindications
Do not use 3.75 mg mirtazapine if:
- Currently taking or stopped an MAOI within 14 days 1
- History of allergic reaction to mirtazapine
- Treating major depressive disorder (dose is inadequate for this indication)
Exercise caution with:
- Personal/family history of bipolar disorder (screen before initiating) 1
- History of agranulocytosis or low white blood cell counts
- Concurrent use of other CNS depressants or serotonergic medications
- Pregnancy/breastfeeding (limited safety data) 1
Practical Recommendation
For insomnia in adults without contraindications, 3.75 mg mirtazapine appears safe based on recent evidence, but this represents off-label use below FDA-approved dosing. The most common side effect would be drowsiness, which is actually the intended effect for insomnia treatment. Monitor for excessive sedation, weight gain, and any mood changes.
For depression treatment, 3.75 mg is inadequate and potentially harmful—it provides no antidepressant benefit while exposing patients to medication risks and delaying effective treatment 4, 5.
The dose should be taken in the evening due to sedating effects 1. Avoid alcohol and benzodiazepines concurrently 1. If discontinuing even this low dose after regular use, taper gradually rather than stopping abruptly to avoid withdrawal symptoms 1.